Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
1.69 USD +3.05% Intraday chart for Milestone Pharmaceuticals Inc. +9.74% +1.20%
08/04 Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting CI
28/03 Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA MT

Evolution of the average Target Price on Milestone Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

ae97de17d5dd35296a8f120df28587e.Ppq8h7HvqgyQMuLqEUN2_VUm57sLix3OPB7DKiz5Y6U.fMOR3_y_5zvZYqeDQiwfrSYQhetF7l6ndWioQX-RVchnotHN-YT-X_pCtw~a9ed172663ee7043c43c658e4652eedb

Analyst Recommendations on Milestone Pharmaceuticals Inc.

Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating MT
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy MT
Oppenheimer Adjusts Milestone Pharmaceuticals' Price Target to $13 From $16, Keeps Outperform Rating MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $16 From $15, Maintains Outperform Rating MT
Piper Sandler Lifts Milestone Pharmaceuticals to Overweight From Neutral, Price Target to $10 From $8 MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $14 From $17, Maintains Outperform Rating MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $17 From $18 Following Q4 Report, Maintains Outperform Rating MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate MT
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate CI
MILESTONE PHARMACEUTICALS : HC Wainwright Starts Milestone Pharmaceuticals at Buy With $20 Price Target MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 3 Study of Etripamil Nasal Spray for Rapid Heart Rate MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.69 USD
Average target price
10.5 USD
Spread / Average Target
+521.30%
High Price Target
25 USD
Spread / Highest target
+1,379.29%
Low Price Target
3 USD
Spread / Lowest Target
+77.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Milestone Pharmaceuticals Inc.

Piper Sandler
TD Cowen
Oppenheimer
Jefferies & Co.
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MIST Stock
  4. Consensus Milestone Pharmaceuticals Inc.